Also known as

FOXO4 DRI · FOXO4-D · Senolytic research peptide

Overview

FOXO4-DRI is an investigational peptide designed to disrupt FOXO4–p53 interaction and is listed on senolytic and longevity-research catalogs. Preclinical literature explores selective clearance of senescent cells in aging models.

It remains an investigational research tool; pages here do not present clinical senolytic protocols. Left Turn Adventures supplies this compound for laboratory and research use only.

Proven benefits

Note: Preclinical / literature endpoints for labs — not established human treatment benefits. Not a protocol.

• FOXO4–p53 disruption endpoints in senescent-cell models

• - Senolytic clearance markers in aging research

• - Tissue rejuvenationadjacent biomarkers where studied

• - p53-pathway pharmacology in senescence designs

• - Comparative senolytic research framing versus small-molecule tools

Results timeline

Note: Illustrative research-observation windows — not a clinical schedule. No dosing.

• Week 12: Early FOXO4–p53 disruption and senescence-marker readouts in preclinical models.

• - Week 3–4: More defined senescent-cell clearance and apoptosis-associated markers in short research windows.

• - Month 2–3: Tissue-function and inflammatory-aging biomarkers in extended senolytic designs.

• - Month 36: Sustained senolytic and longevity-model observations where longer studies are used.

Footer RUO

The catalog, not a clinic

For laboratory and research use only. Not for human or animal consumption. Products are sold solely to qualified researchers and licensed laboratories. No dosing or reconstitution on this page.